Citric Acid

Citric Acid

SCHEMBL119893

C[N+](C)(C)CCO.C[N+](C)(C)CCO.C[N+](C)(C)CCO.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-]

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BHRH2IMPA1

The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CA4 P22748 1/20 0.59
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP3A4 P08684 1/20 0.44
SLC5A7 Q9GZV3 1/20 0.44
BBOX1 O75936 3/20 0.33
GALR3 O60755 1/20 0.32
SLC22A16 Q86VW1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Citric Acid SCHEMBL692736 1.00 CA4 (0.59) CA4MEN1LMNAKMT2ACYP3A4
Citric Acid SCHEMBL20456925 1.00 CA4 (0.59) CA4MEN1LMNAKMT2ACYP3A4
Citric Acid SCHEMBL275858 1.00 CA4 (0.59) CA4MEN1LMNAKMT2ACYP3A4
Citric Acid SCHEMBL31726489 0.98 CA4 (0.57) CA4MEN1LMNAKMT2ACYP3A4
Citric Acid SCHEMBL3871318 0.98 CA4 (0.57) CA4MEN1LMNAKMT2ACYP3A4
Citric Acid SCHEMBL275857 0.98 CA4 (0.57) CA4MEN1LMNAKMT2ACYP3A4
Citric Acid SCHEMBL3998452 0.98 CA4 (0.57) CA4MEN1LMNAKMT2ACYP3A4
Citric Acid SCHEMBL15323424 0.98 CA4 (0.57) CA4MEN1LMNAKMT2ACYP3A4
Citric Acid SCHEMBL3998443 0.98 CA4 (0.57) CA4MEN1LMNAKMT2ACYP3A4
Citric Acid SCHEMBL1154430 0.98 CA4 (0.57) CA4MEN1LMNAKMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 901 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12551441-B2 Water soluble silicon-containing granulate BIO MINERALS NV (BE) 2026-02-17 US claimed
US-20260026538-A1 COMPOSITIONS COMPRISING CHOLINE AND OMEGA-3 FATTY ACID TO NUTRITIONALLY ENHANCE FOOD PRODUCTS INGENUITY FOODS, INC. (US) 2026-01-29 US claimed
US-20250304851-A1 METHODS AND COMPOSITIONS USED IN CONTROLLING FORMATION SAND PRODUCTION, PROPPANT FLOWBACK, AND FINES MIGRATION HALLIBURTON ENERGY SERVICES, INC 2025-10-02 US claimed
US-12426615-B2 Compositions comprising choline and omega-3 fatty acid to nutritionally enhance food products INGENUITY FOODS, INC. (US) 2025-09-30 US claimed
CN-120022522-A Drug-loaded microneedle, drug-loaded microneedle patch and electrically-controlled drug release microneedle system 成都邦迈医创科技有限公司 2025-05-23 CN claimed
WO-2025088479-A1 PROCESS FOR RECYCLING LITHIUM BATTERIES UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2025-05-01 WO claimed
CN-119896763-A Pasty biological tissue adhesive capable of being coated and preparation method and application thereof 哈尔滨工业大学 2025-04-29 CN claimed
CN-119556538-A Alkaline stripping liquid for silicon-based surface composite film and stripping method thereof 湖北兴福电子材料股份有限公司 2025-03-04 CN claimed
US-20250059446-A1 MULTIVALENT IONIC LIQUIDS AS PROCESS AIDS FOR BITUMEN EXTRACTION STERLING SPECIALTY CHEMICALS HOLDING UK LIMITED (GB) 2025-02-20 US claimed
US-12171224-B2 Choline salt and ammonium-free adjuvants for water conditioning and agricultural formulations SPECIALTY OPERATIONS FRANCE (FR) 2024-12-24 US claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
CN-1290125-A Enhancement of metal molluscicides by ethylene diamine disuccinic acid NEUDORFF W GMBH KG (DE) 2001-04-04 CN claimed
US-6048728-A PROPAGATING CELLS; CONTACTING CELLS WITH A CULTURE MEDIUM, WHEREIN SAID COMPONENTS ARE SUFFICIENT TO INCREASE THE CULTURES PRODUCTIVE SHELF LIFE BY MAINTAINING CELLS IN A PROPAGATION STATE CHIRON CORPORATION (US) 2000-04-11 US claimed
US-5939076-A Composition and method for treating or alleviating migraine headaches ALLOCCA TECHICAL, INC. (US) 1999-08-17 US claimed
WO-1999023881-A1 COMPOSITION AND METHOD FOR PREVENTING OR ALLEVIATING MIGRAINE HEADACHES ALLOCCA TECHNICAL, INC. (US) 1999-05-20 WO claimed
EP-0435911-B1 CELL CULTURE MEDIUM FOR ENHANCED CELL GROWTH, CULTURE LONGEVITY AND PRODUCT EXPRESSION CETUS ONCOLOGY CORP (US) 1996-03-13 EP claimed
EP-0501776-A1 Stabilization of subterranean formations HALLIBURTON COMPANY (US) 1992-09-02 EP claimed
US-5097904-A Flow control agents in enhanced oil recovery HALLIBURTON COMPANY (US) 1992-03-24 US claimed
EP-0435911-A1 CELL CULTURE MEDIUM FOR ENHANCED CELL GROWTH, CULTURE LONGEVITY AND PRODUCT EXPRESSION. CETUS CORP (US) 1991-07-10 EP claimed
WO-1990003430-A1 CELL CULTURE MEDIUM FOR ENHANCED CELL GROWTH, CULTURE LONGEVITY AND PRODUCT EXPRESSION CETUS CORPORATION (US) 1990-04-05 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12171224-B2 Choline salt and ammonium-free adjuvants for water conditioning and agricultural formulations ACHE, PHOSPHO1, CHAT CA4 1172/4885MEN1 2734/4885LMNA 3927/4885
US-12551441-B2 Water soluble silicon-containing granulate SI, GIPR, VIP CA4 1064/4885MEN1 2488/4885LMNA 1265/4885
US-20260026538-A1 COMPOSITIONS COMPRISING CHOLINE AND OMEGA-3 FATTY ACID TO NUTRITIONALLY ENHANCE FOOD PRODUCTS ELOVL3, ELOVL6, ELOVL1 CA4 2963/4885MEN1 3184/4885LMNA 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.